Effectiveness of Chemo-Immunotherapy (CIT) and Novel Therapies in Second or Later Line of Therapy (2L+) for Patients with Relapsed/Refractory (R/R) Aggressive Large B-Cell Lymphoma (LBCL)

被引：1

作者：

Nastoupil, Loretta J. ^{[1
]}

Andersen, Clark R. ^{[1
]}

Ayers, Amy ^{[1
]}

Wang, Yucai ^{[2
]}

Habermann, Thomas M. ^{[2
]}

Chihara, Dai ^{[1
]}

Kahl, Brad S. ^{[3
]}

Link, Brian K. ^{[4
]}

Cohen, Jonathon B. ^{[5
]}

Martin, Peter ^{[6
]}

Lossos, Izidore S. ^{[7
]}

Casulo, Carla ^{[8
]}

Lin, Ruitao ^{[1
]}

Li, Ziyi ^{[1
]}

Larson, Melissa C. ^{[2
]}

Maurer, Matthew J. ^{[2
]}

Huynh, Lynn ^{[9
]}

Gao, Chi ^{[9
]}

Ramasubramanian, Ramya ^{[9
]}

Sheng, Mei ^{[9
]}

Mutebi, Alex ^{[10
]}

Wang, Tongsheng ^{[10
]}

Jun, Monika ^{[10
]}

Wang, Anthony ^{[11
]}

Kamalakar, Rajesh ^{[11
]}

Kalsekar, Anupama ^{[10
]}

Cerhan, James R. ^{[2
]}

Flowers, Christopher R. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[2] Mayo Clin, Rochester, MN USA

[3] Washington Univ, Sch Med St Louis, St Louis, MO USA

[4] Univ Iowa, Carver Coll Med, Iowa City, IA USA

[5] Emory Univ, Atlanta, GA USA

[6] Weill Cornell Med Coll, New York, NY USA

[7] Univ Miami Hlth Syst, Miami, FL USA

[8] Univ Rochester, Med Ctr, Rochester, NY USA

[9] Anal Grp Inc, Boston, MA USA

[10] Genmab, Princeton, NJ USA

[11] AbbVie Inc, Chicago, IL USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-174497

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[31] Cost-Effectiveness of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Treatment of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Parker, Christopher
Liu, Fei Fei
Deger, Kristen
Franco-Villalobos, Conrado
Proskorovsky, Irina
Keating, Scott J.
Sorensen, Sonja
Dorman, Emily
BLOOD, 2021, 138
[32] Glofitamab monotherapy in patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL): extended follow-up and landmark analyses from a pivotal phase II study
Dietrich, S.
Falchi, L.
Carlo-Stella, C.
Morschhauser, F.
Hutchings, M.
Bachy, E.
Cartron, G.
Khan, C.
Tani, M.
Martinez-Lopez, J.
Bartlett, N.
Salar, A.
Brody, J.
Leppa, S.
Mulvihill, E.
Lundberg, L.
Relf, J.
Xie, Y.
Bottos, A.
Humphrey, K.
Dickinson, M.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 208 - 208
[33] Association of pretreatment (preTx) tumor characteristics and clinical outcomes following second-line (2L) axicabtagene ciloleucel (axi-cel) versus standard of care (SOC) in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
Locke, Frederick L.
Chou, Justin
Vardhanabhuti, Saran
Perbost, Regis
Dreger, Peter
Hill, Brian T.
Lee, Catherine
Zinzani, Pier Luigi
Kroeger, Nicolaus
Lopez-Guillermo, Armando
Greinix, Hildegard
Zhang, Wangshu
Tiwari, Gayatri
To, Christina Ann
Cheng, Paul C.
Bot, Adrian
Shen, Rhine
Filosto, Simone
Galon, Jerome
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[34] Polatuzumab Vedotin in Relapsed and Refractory (r/r) Large B-Cell Lymphoma (LBCL): Real-World Data of the German National Compassionate Use Program (CUP)
Liebers, Nora
Duell, Johannes
Norenberg, Daniel
Kaebisch, Eva
Kerkhoff, Andrea
Acker, Fabian
Fuhrmann, Stephan
Leng, Corinna
Welslau, Manfred
Chemnitz, Jens
Middeke, Jan Moritz
Weber, Thomas
Trappe, Ralf Ulrich
Pfannes, Roald
Liersch, Ruediger
Spoer, Christian
Gebauer, Niklas
Fuxius, Stefan
Caille, Leandra
Pott, Christiane
Koenecke, Christian
Holtick, Udo
Geer, Thomas
Keller, Ulrich
Claus, Rainer
Mougiakakos, Dimitrios
Mayer, Stephanie
Huttmann, Andreas
Trummer, Arne
Wulf, Gerald
Brunnberg, Uta
Bullinger, Lars
Hess, Georg
Mueller-Tidow, Carsten
Glass, Bertram
Lenz, Georg
Dreger, Peter
Dietrich, Sascha
BLOOD, 2020, 136
[35] Durable Efficacy and Manageable Safety in Patients Aged ≥75 Years With Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL) Treated With Tisagenlecleucel in the Real-World Setting
Landsburg, Daniel J.
Heim, Michael
Moskop, Amy
Foley, Stephen Ronan
Hill, Brian T.
Schofield, Grant
Jacobson, Caron A.
Jaglowski, Samantha
Locke, Frederick L.
Ram, Ron
Riedell, Peter A.
Shah, Gunjan L.
Popplewell, Leslie L.
Tiwari, Ranjan
Lim, Stephen
Maier, Harald
Majdan, Marta
Pasquini, Marcelo C.
Frigault, Matthew J.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S471 - S471
[36] Clinical Pharmacology of CTL019 in Patients with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)
Awasthi, Rakesh
Tam, Constantine S.
Jaeger, Ulrich
Jaglowski, Samantha
Foley, Stephen Ronan
Van Besien, Koen
Wagner-Johnston, Nina D.
Kersten, Marie Jose
Schuster, Stephen J.
Salles, Gilles Andre
Maziarz, Richard Thomas
Anak, Oezlem
Pacaud, Lida Bubuteishvili
Gazi, Lucien
Waldron, Edward
Hamilton, Jason
Pruteanu, Iulian
Tai, Feng
Mueller, Karen Thudium
Waller, Edmund K.
BLOOD, 2017, 130
[37] Magrolimab in Combination with Rituximab plus Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Maakaron, Joseph
Asch, Adam S.
Popplewell, Leslie L.
Collins, Graham P.
Flinn, Ian W.
Ghosh, Nilanjan
Keane, Colin
Ku, Matthew
Mehta, Amitkumar
Roschewski, Mark
O'Hear, Carol
Ren, Xuehan
Villa, Bertha
Lal, Indu
Smith, Sonali M.
Advani, Ranjana H.
BLOOD, 2022, 140 : 3728 - 3730
[38] Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Patients: A Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy
Di Rocco, Alice
Di Rocco, Arianna
Farcomeni, Alessio
Petrucci, Luigi
De Luca, Giulia
Mazzon, Federico
Martelli, Maurizio
Foa, Robin
BLOOD, 2019, 134
[39] AN UPDATED TWO-YEAR SURVIVAL ANALYSIS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) IN RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA (R/R-LBCL)
Diakite, I
Lin, V. W.
Klijn, S.
Navale, L.
Purdum, A. G.
Fenwick, E.
Botteman, M.
van Hout, B.
VALUE IN HEALTH, 2019, 22 : S41 - S41
[40] Second line immune targeted therapies in relapsed or refractory diffuse large B-cell lymphoma: A network meta-analysis.
Mohamed, Aneesha Fathima Syed
Kandikatla, Renuka
Yakkala, Vinod Kumar
Solodokin, Loriel
Doucette, Joanne
Yunusa, Ismaeel
Eguale, Tewodros
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →